Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to KnowZacks Investment Research · 4 days ago
Novavax (NVAX) Stock Declines While Market Improves: Some Information for InvestorsZacks Investment Research · 5 days ago
Novavax (NASDAQ:NVAX) Shares Down 9.1% – Here’s What HappenedDefense World · Oct 18, 2026
Novavax shareholder Shah Capital to step back from activist roleReuters · Oct 16, 2026
Moderna and Novavax Stocks Slump as Biotech's Rally Takes a BreatherBarrons · Oct 16, 2026
Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady24/7 Wall Street · Oct 16, 2026Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.38 | -$0.32 | Beat |
| May 6, 2026 | -$0.25 | -$0.06 | Beat |
| Feb 26, 2026 | -$0.66 | $0.11 | Beat |
| Nov 6, 2025 | -$1.08 | -$1.25 | Miss |
| Aug 6, 2025 | -$0.07 | $0.62 | Beat |
| May 8, 2025 | $0.71 | $2.93 | Beat |